The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Akari Therapeutics Plc ADR shares valued at $9,400 were purchased by Gaslightwala Abizer on Aug 21 ’25. At $0.94 per share, Gaslightwala Abizer acquired 10,000 shares. The insider’s holdings grew to 287,574 shares worth approximately $0.23 million following the completion of this transaction.
Also, Gaslightwala Abizer purchased 8,000 shares, netting a total of over 7,440 in proceeds. Following the buying of shares at $0.93 each, the insider now holds 295,574 shares.
Before that, Gaslightwala Abizer had added 3,000 shares to its account. In a trade valued at $2,700, the CEO bought Akari Therapeutics Plc ADR shares for $0.90 each. Upon closing the transaction, the insider’s holdings increased to 3,000 shares, worth approximately $0.24 million.
As published in their initiating research note from Maxim Group on July 18, 2025, Akari Therapeutics Plc ADR [AKTX] has been a Buy and the price target has been revised to $5. Analysts at B. Riley FBR upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in early January. As of February 08, 2018, B. Riley FBR Inc. has initiated its “Neutral” rating for AKTX. Earlier on September 22, 2017, William Blair upgraded its rating. Their new recommendation was “an Outperform” for AKTX stock which previously was a “a Mkt perform”.
Analyzing AKTX Stock Performance
On last trading session, Akari Therapeutics Plc ADR [NASDAQ: AKTX] rose 5.11% to $0.79. The stock’s lowest price that day was $0.68, but it reached a high of $0.83 in the same session. During the last five days, there has been a surge of approximately 0.46%. Over the course of the year, Akari Therapeutics Plc ADR shares have dropped approximately -75.62%.
Is Akari Therapeutics Plc ADR subject to short interest?
Stocks of Akari Therapeutics Plc ADR saw a sharp steep in short interest on 2025-08-29 dropping by 18678.0 shares to 24554.0. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 43232.0 shares. A decline of -76.07% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 0.55 of the overall float, the days-to-cover ratio (short ratio) decline to 0.55.
Which companies own the most shares of Akari Therapeutics Plc ADR (AKTX)?
In terms of Akari Therapeutics Plc ADR share price expectations, FactSet research, analysts set an average price target of 30 in the next 12 months, up nearly 3900.0% from the previous closing price of $0.75. Analysts anticipate Akari Therapeutics Plc ADR stock to reach 30 by 2025, with the lowest price target being 30. On May 31, 2017, Chardan Capital Markets assigned a price target of “a Neutral” to the stock and upgraded coverage with a $6.
